Browsing Tag
National Stock Exchange of India
111 posts
Sumeet Industries reports Rs 1,053.8cr FY26 income as SUMEETINDS margin recovery gains traction
Find out how Sumeet Industries’ FY26 earnings, Nakoda asset bid and polyester expansion could reshape its next growth phase.
Valor Estate FY26 results: DBREALTY turns profitable as debt falls by Rs 1,136cr
Find out how Valor Estate’s FY26 turnaround, debt reduction and DBREALTY stock setup could reshape investor sentiment in Indian real estate.
NTPC stock in focus as #NTPC Q4 profit jump strengthens India power sector earnings story
NTPC’s Q4 profit surge and dividend sharpen the power transition debate. Read why #NTPC investors are watching cash flow and renewables.
Is Divi’s Laboratories still worth its premium after a steady Q4 profit beat?
Divi’s Laboratories posted Q4 profit growth and a ₹30 dividend, but margin pressure keeps valuation in focus. Read what #DIVISLAB signals now!
Hindalco Industries Q4 results expose the gap between India strength and Novelis disruption risk
Hindalco’s Q4 profit fell on Novelis disruption, but record EBITDA and India strength complicate the story. Read what #HINDALCO signals now!
Is Eicher Motors quietly turning Royal Enfield into a stronger premium mobility engine?
Eicher Motors rallied after Q4 FY26 profit and revenue beat expectations. Find out what this means for #EICHERMOT investors today!
Paytm block deal puts #PAYTM in focus as institutional buyers absorb Elevation Capital stake sale
Paytm saw a ₹964 crore block deal as Elevation Capital trimmed stake. Find out what this means for #PAYTM investors today!
JSW Cement and Pine Labs block deals put post-listing investor appetite under fresh scrutiny
JSW Cement and Pine Labs saw large block deals as investors trimmed stakes. Find out what this means for #JSWCEMENT and #PINELABS today!
Aurobindo Pharma stock slips as USFDA OAI classification tests investor confidence in #AUROPHARMA
Aurobindo Pharma faces USFDA OAI pressure at a Telangana unit. Find out why this matters for #AUROPHARMA investors today!
Can Gujarat Themis Biosyn turn a Japanese acquisition into a global CDMO platform?
Gujarat Themis Biosyn is buying MicroBiopharm Japan for ₹1,300 crore. Find out why this CDMO bet matters for #GUJTHEM today!